Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report)'s share price traded down 8.5% on Thursday . The company traded as low as $1.18 and last traded at $1.19. 753,183 shares were traded during trading, an increase of 143% from the average session volume of 309,784 shares. The stock had previously closed at $1.30.
Analyst Upgrades and Downgrades
Separately, HC Wainwright assumed coverage on Cardiol Therapeutics in a research report on Monday, June 2nd. They set a "buy" rating and a $9.00 price objective for the company.
Get Our Latest Stock Report on CRDL
Cardiol Therapeutics Stock Performance
The company has a debt-to-equity ratio of 0.01, a current ratio of 3.26 and a quick ratio of 3.26. The stock has a 50-day moving average price of $1.30 and a two-hundred day moving average price of $1.21. The stock has a market cap of $98.35 million, a PE ratio of -3.50 and a beta of 1.04.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp bought a new position in shares of Cardiol Therapeutics in the 4th quarter valued at about $25,000. Cetera Investment Advisers bought a new position in shares of Cardiol Therapeutics in the 4th quarter valued at about $56,000. Virtu Financial LLC bought a new position in shares of Cardiol Therapeutics in the 4th quarter valued at about $61,000. Atria Investments Inc bought a new position in shares of Cardiol Therapeutics in the 4th quarter valued at about $174,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of Cardiol Therapeutics in the 4th quarter valued at about $398,000. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Further Reading
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
